The continuous MIPI score of 5.75 places this patient in the intermediate risk group.
Median overall survival for the intermediate risk group: ~51 months.
The simplified MIPI (sMIPI) point score is 3, consistent with low risk.
Enter a Ki-67 value to also calculate the biological MIPI (MIPIb), which refines risk stratification using tumor proliferation.
Next stepIntermediate- and high-risk patients typically receive immunochemotherapy, with or without autologous stem cell transplantation depending on age and comorbidities.